Viridian Therapeutics, Inc.\DE cotiza a 18.30 USD y tiene una capitalización bursátil de $2.1B. En los últimos 12 meses ha facturado $71M con un margen de flujo de caja libre del -390.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-1.05 | $-0.90 | $-1.08 |
| Estimado | $-0.97 | $-1.03 | $-1.08 | $-1.00 |
| Sorpresa | — | -1.9% | +16.7% | -8.0% |
| Métrica | VRDN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -512.9% | -38.6% | -474.3% |
| Net Margin | -483.6% | -33.6% | -450.0% |
| FCF Margin | -390.8% | -13.9% | -376.9% |
| ROE | -47.4% | -40.4% | -7.0% |
| ROA | -38.1% | -32.0% | -6.1% |
| Current Ratio | 12.65 | 2.84 | +9.81 |
| Debt / Equity | — | 0.28 | — |